Dario A. Vignali, PhD
Campus: 200 Lothrop Street
Office: E1052 BSTWR
Lab: E1000-12B - 15A
- BSc, Immunology and Medical Microbiology, North East London Polytechnic, 1985
- PhD, Immunology of Infectious Diseases, University of London, 1988
- UPMC Endowed Professor and Vice Chair
Our research focuses on various aspects of T cell function:
- Regulatory T cells (Tregs):
Identification of novel Treg molecules and their function; mechanism of Treg function; IL-35 signaling and mechanism of action; regulation of Treg stability via the Nrp1 pathway; biology of IL-35 and Nrp1 in cancer, mucosal immunity (particularly asthma and intestinal pathogens) and autoimmunity (particularly type 1 diabetes).
- Inhibitory Molecules:
LAG3 signaling and mechanism of action; synergy between LAG3 and other inhibitory receptors, particularly PD1; immune modulation by LAG3 and PD1 in tumors, mucosal immunity (particularly asthma and intestinal pathogens) and autoimmunity (particularly type 1 diabetes).
- Type 1 diabetes:
In additional to the topics above: importance of TCR specificity and affinity in the diabetogenic or regulatory potential of T cells; mechanisms that regulate T cell islet entry and diabetogenicity.
T cell receptor (TCR):CD3 complex: Molecular initiation and control of TCR signal transduction; role of CD3 in T cell development and function.
Delgoffe GM, Woo SR, Turnis ME, Gravano DM, Guy C, Overacre AE, Bettini ML, Vogel P, Finkelstein D, Bonnevier J, Workman CJ, Vignali DA.Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature. 2013 Sep 12;501(7466):252-6.
Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, Jiang S, Kuchroo VK, Mathis D, Roncarolo MG, Rudensky A, Sakaguchi S, Shevach EM, Vignali DAA*, Ziegler SF. Regulatory T cells: recommendations to simplify the nomenclature. Nature Immunology 2013 Apr;14(4):307-8
Herold KC, Vignali DAA, Cooke A, Bluestone JA. Type I diabetes: translating mechanistic observations into effective clinical outcomes. Nature Reviews Immunology 2013 (in press). [Invited Review]
Guy C, Vignali KM, Temirov J, Bettini ML, Overacre AE, Smeltzer M, Zhang H, Huppa JB, Tsai Y-H, Lobry C, Xie J, Dempsey PJ, Crawford HC, Aifantis I, Davis MM, Vignali DAA. Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. Nature Immunology 14:262-270, 2013. [Issue Cover] [PMID: 23377202]
Vignali DAA, Kuchroo VK. IL-12 Family Cytokines: Immunological Playmakers. Nature Immunology 13:722-728, 2012. [PMID: 22814351]
Turnis ME, Korman AJ, Drake CG, Vignali DAA. Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more. OncoImmunology 1:1172-1174, 2012. [PMID: 23170269; PMCID: 3494635]
Bettini ML, Pan F, Bettini M, Finkelstein D, Rehg JE, Floess S, Bell BD, Ziegler SF, Huehn J, Pardoll DM, Vignali DAA. Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency. Immunity 36:717–730, 2012. [Issue Cover] [PMID: 22579476; PMCID: 3361541]
Bettini M, Castellaw A, Lennon G, Burton AR, Vignali DAA. Prevention of autoimmune diabetes by ectopic pancreatic beta cell expression of Interleukin-35. Diabetes 61:1519-1526, 2012. [PMID: 22427377; PMCID: 3357277]
Collison LC*, Delgoffe GM*, Guy C, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG, Murray PJ, Vignali DAA. The composition and signaling of the IL-35 receptor are unconventional. Nature Immunology 13:290-299, 2012. [PMID: 22306691; PMCID: 3529151]